ASCO 2013 Gastrointestinal Cancers Symposium Roundup ENJOY friends

coloCan said:

Pete,try this, its easier, i think:

www.cancernetwork.com/print/article/10165/2125107?GUID=702A03F0-7B62-493F-83A5-DFFCB4A6F5D2&rememnerme=1&ts=31012013&printable=true

 

PS-check articles linked to this at bottom as well as the one on

 three subtypes,if you haven;t read that already

from the subtypes, guess whose tumour is flying to california for analysis while the living NED body is off to germany.

I decided to document my tumour and biology as fully as possible so that when I start getting friends who follow in the germany immuntherapy clinic set of treatments we can see hopefully a pattern in therapy response and colorectal subtype. I ordered the test, got no idea what it costs, I will publish the test results when I get them. at least 3 weeks.

So the question is what subtype are you ? 

I want to know, maybe some others ?

Three Colorectal Subtypes

Among the validation dataset, 21.5% of samples were subtype A, 62% were subtype B, and 16.5% were subtype C. The major characteristics that differed among these subtypes were the epithelial-to mesenchymal transition, a marker associated with more aggressive tumors; defects in mismatch repair genes, which are responsible for correcting DNA replication errors that are associated with high rates of genetic mutations; and rate of cell proliferation.

According to the results, subtype A and B have better clinical outcomes compared to subtype C patients. Subtype A and B patients may benefit from adjuvant chemotherapy. A decade-long follow-up showed that subtype C patients had the worse prognosis and did not benefit from adjuvant chemotherapy.

Subtypes A and C have a higher mutation frequency due to the mismatch repair deficiency in these two subtypes. All of the subtypes included tumors with a BRAFmutation—39% of subtype A, 2% of subtype B, and 16% of subtype C harbored a BRAFmutation. Subtypes A and C had more frequent mutations in PI3KCA and KRAScompared to subtype B.

Because there are not just one or two mutations unique to each subtype, Bernards said that the only way to unambiguously assign patients to each of the three subtypes is through gene expression analysis. Agendia, a molecular cancer diagnostics company with headquarters in Amsterdam, and laboratories based in Irvine, California, has developed a gene profile to identify each of the three colorectal cancer subtypes. “We will publish this gene signature in the near future,” noted Bernards.

coloCan said:

and then there's this thought (tho i've yet to see the original

article or specifics on this, i just cite it to show how there are so many views on the nature CRC,including causation,development,spread and sometimes defeat)

www.medicalnewstoday.com/releases/255506.php

Plus,recently helio.com had an article that brought up the possibility that CRC may be a different disease in older people than younger

Then,almost every other day researchers come up with another gene or protein that might be involved someway with CRC (PAK1, PAK4;USP22;SALL4;Foxp3 were all cited in the past two-three days)...and this is from this date:

http://medicalxpress.com/news/2013-01-cancer-cells-rewire-metabolism-survive.html

From what i've seen here on CSN,hardly anyone seems to get tested for BRAF of PI3K and even if we did, not much seems to be available drug wise,convenionally........

 

 

 

 

the last study fascinating, proof of why my earlier tktl1 protien test works.

seems reasonable for some to minimise sugar, so many variables and conventional wants large trials without subtyping.and other tests.

personalised treatment the future

hugs,

pete

ps i wish more crc would read and study and comment here, alas my friend its us. the more brains the better, we might find another curative pathway.